This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

MDRP 2022 — Medicaid Drug Rebate Program Summit
Delivered as a Hybrid Event
October 12-14, 2022 | JW Marriott ChicagoChicago, IL

Matthew Fornataro
Partner at Arnold & Porter

Profile

Matt Fornataro's practice focuses on life sciences and health care regulation, and he works with a range of companies on compliance, enforcement, contracting, and public policy matters. His clients include established pharmaceutical, biotechnology, and medical device manufacturers, as well as related trade societies, and he also counsels clients with emerging products and therapies.

Mr. Fornataro counsels on pricing and government price reporting compliance issues, and he regularly advises manufacturers on Medicaid, Medicare Part B, Department of Veterans Affairs, and 340B Program requirements, as well as state drug price reporting laws. Mr. Fornataro assists clients with restatements, investigations, and litigation related to drug price reporting, and he drafts public comments on proposed rules and guidance.

Mr. Fornataro also counsels on life sciences and healthcare fraud and abuse issues, including particularly matters governed by the federal Anti-Kickback Statute. He assists pharmaceutical, biotechnology, and medical device manufacturers with complex risk analyses, internal reviews and investigations, OIG Advisory Opinion requests, and government audits and investigations.

Mr. Fornataro is Co-Chair of Arnold & Porter's Pride Affinity Group for LGBTQ+ attorneys, and he was selected by the National LGBT Bar Association as one of its 2014 "Best LGBT Lawyers Under 40" for his professional accomplishments and pro bono work for causes of importance to the LGBTQ+ community.

Agenda Sessions

  • Acquisitions and Divestitures for Emerging, Small and Mid-Sized Pharma

    2:55pm